New vitamin D analogs.

What It Covers

This review looks at Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).

1,25-(OH)2D3 (calcitriol) controls parathyroid gland growth and suppresses the synthesis and secretion of parathyroid hormone.

Because of this, 1,25-(OH)2D3 has been used successfully for the treatment of secondary hyperparathyroidism, which almost always accompanies renal failure.

Who the Included Studies Covered

This has led to the development of vitamin D analogs that retain the suppressive action on PTH and parathyroid gland growth, but that have less calcemic and phosphatemic activity.

Currently, two analogs, 19-nor-1,25-(OH)2D2 and 1,alpha(OH)D2, are being used for the treatment of secondary hyperparathyroidism in the United States, and two are being used in Japan, 22-oxa-calcitriol and 1,25-(OH)2-26,27F6 D3.

What Was Measured

Because of this, 1,25-(OH)2D3 has been used successfully for the treatment of secondary hyperparathyroidism, which almost always accompanies renal failure.

However, the potent effect of 1,25-(OH)2D3 on intestinal calcium and phosphorus absorption and bone mineral mobilization often leads to the development of hypercalcemia and hyperphosphatemia precluding 1,25-(OH)2D3 therapy.

Topics PubMed links to this paper include Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Parathyroid Glands, Parathyroid Hormone and Vitamin D.

What This Means in Plain Language

This is a review of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Kidney international. Supplement), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.